1. Home
  2. ALTO vs OCGN Comparison

ALTO vs OCGN Comparison

Compare ALTO & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ALTO

Alto Ingredients Inc.

HOLD

Current Price

$4.99

Market Cap

420.7M

Sector

Industrials

ML Signal

HOLD

Logo Ocugen Inc.

OCGN

Ocugen Inc.

HOLD

Current Price

$1.46

Market Cap

419.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALTO
OCGN
Founded
2003
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
420.7M
419.8M
IPO Year
2005
2014

Fundamental Metrics

Financial Performance
Metric
ALTO
OCGN
Price
$4.99
$1.46
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.75
AVG Volume (30 Days)
2.5M
6.2M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
119.51
31.58
EPS
0.05
N/A
Revenue
$917,927,000.00
N/A
Revenue This Year
$6.66
N/A
Revenue Next Year
$0.43
$1,718.38
P/E Ratio
$102.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$0.90
52 Week High
$6.00
$2.73

Technical Indicators

Market Signals
Indicator
ALTO
OCGN
Relative Strength Index (RSI) 45.05 58.60
Support Level $4.27 $1.38
Resistance Level $5.07 $1.58
Average True Range (ATR) 0.36 0.08
MACD -0.07 0.03
Stochastic Oscillator 13.04 91.94

Price Performance

Historical Comparison
ALTO
OCGN

About ALTO Alto Ingredients Inc.

Alto Ingredients Inc is a producer and distributor of specialty alcohols, renewable fuels and essential ingredients in the United States. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, and Western production.

About OCGN Ocugen Inc.

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Share on Social Networks: